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SUMMARY
 
Activins and inhibins, which belong to the TGF
 

 
 family, are composed of dif-
ferent combinations of 
 

 
-, 
 

 
A-, and 
 

 
B-subunits, resulting in inhibin A (
 

 
A), inhibin B
(
 

 
B), activin A (
 

 
A
 

 
A), activin B (
 

 
B
 

 
B), and activin AB (
 

 
A
 

 
B). They regulate several cell
functions, acting as paracrine/autocrine factors. Their actions, which depend on binding to
specific receptors, are also modulated by follistatin. Gastroenteropancreatic (GEP) endo-
crine cells and endocrine tumors (ETs) produce several growth factors, but it is not well
known whether they express follistatin and the various inhibin/activin subunits. We studied
their expression in 65 GEP ETs using immunohistochemistry (IHC) and in situ hybridization
(ISH). The 
 

 
-subunit and follistatin were not identified in normal GEP endocrine cells and
were poorly expressed in ETs. A 
 

 
A-subunit immunoreactivity (IR) was detected in A-, G-,
EC-, and GIP-cells, while 
 

 
B-chain IR was present only in D-cells. The mRNAs encoding for
these molecules were poorly expressed in normal tissues. 
 

 
A- and 
 

 
B-subunits were identi-
fied in several ETs by both IHC and ISH: 
 

 
A-subunit mainly in G-cell and A-cell ETs, and 
 

 
B-
subunit in D-cell, A-cell, and EC-cell ETs. Our results demonstrate a differential expression
of activin/inhibin subunits among different types of GEP endocrine cells and related tu-
mors, suggesting a role in modulation of biological functions of these normal and neoplas-
tic endocrine cells.
 
(J Histochem Cytochem 52:217–225, 2004)
 
I
 
nhibins and activins
 
 are regulatory factors first iso-
lated from gonadal fluids on the basis of their ability
to modulate pituitary FSH release in a long-loop endo-
crine fashion (Vale et al. 1986). They are both disul-
fide-linked dimeric proteins belonging to the trans-
forming growth factor-
 

 
 (TGF
 

 
) superfamily (Massagué
1987). Inhibins are heterodimers composed of an
 

 
-subunit and one of two 
 

 
-subunits, 
 

 
A or 
 

 
B, result-
ing in inhibin A (
 

 
-
 

 
A) or inhibin B (
 

 
-
 

 
B), respec-
tively (Mason et al. 1986; Stewart et al. 1986). Activins
consist of homo/heterodimers of any combination of
the 
 

 
-subunits, resulting in activin A (
 

 
A-
 

 
A), activin
B (
 

 
B-
 

 
B), and activin AB (
 

 
A-
 

 
B) (Ling et al. 1986;
Vale et al. 1986). The identification of inhibin/activin
subunits in a wide variety of reproductive and non-
reproductive tissues (Meunier et al. 1988; Wada et al.
1996; Zheng and Lauchlan 1999) has suggested that
these peptides, in addition to regulating FSH secretion
in pituitary, may have a greatly expanded biological
role. These functions include the regulation of steroid
production in gonads and adrenal glands (Hsueh et al.
1987; Spencer et al. 1992), insulin secretion in pancre-
atic islets (Totsuka et al. 1988; Florio et al. 2000), gly-
cogenolysis in hepatocytes (Mine et al. 1989), and
modulation of cell growth and maturation of several
fetal and adult tissues (Halvorson and DeCherney
1996). In these sites, activins and inhibins have been
shown to locally exert their biological actions through a
paracrine and/or autocrine mechanism (DePaolo et al.
1991; Bilezikjian and Vale 1992; Mather et al. 1992).
Activins’ actions are mediated by binding to spe-
cific receptors with serine/threonine kinase activity
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(Mathews 1994). Specific receptors with high affinity
for inhibin have not been identified (Risbridger et al.
2001), although inhibin has been found to bind to ac-
tivin type II receptors (Halvorson and DeCherney
1996).
In addition to activin receptors, activin actions are
also modulated by follistatin, which inhibits its func-
tions, but with approximately one third of the potency
of inhibin (DePaolo et al. 1991). Follistatin, initially
isolated from porcine follicular fluid, is a single-chain
peptide that does not share any structural relationship
with inhibins or activins (Ueno et al. 1987) but shows
structural homology with the epidermal growth factor
and with a group of enzyme inhibitors of the Kazal
family (Risbridger et al. 2001). As demonstrated by Shi-
monaka et al. (1991), follistatin blocks activin func-
tion by binding to the 
 

 
-subunit. In addition to the
ovary, follistatin is expressed in several tissues in both
rats and humans. Using Northern analyses, Shimasaki
et al. (1989) identified follistatin gene expression in
rat brain and kidney. Moreover, immunoreactivity for
follistatin was found in several human cells including
Leydig cells, pituitary somatotrophs, pancreatic 
 

 
-cells,
thyroid follicular cells, cortical cells of the adrenal
glands, neurons of the brain cortex, and monocytoid
cells of the bone marrow (Wada et al. 1996). The bio-
logical meaning of this distribution is not yet clear,
but it has been suggested that in these sites follistatin
can modulate actions of inhibins and activins (Wada
et al. 1996).
Gastrointestinal and pancreatic endocrine (GEP)
cells belong to the diffuse neuroendocrine system and
are characterized by production of several hormones
or amines, whose expression allows their identifica-
tion. In recent years, some investigations have demon-
strated that normal endocrine cells of the digestive sys-
tem, in addition to hormones, express growth factors
and growth factor receptors (Bordi et al. 1994;
Kuroda et al. 1995; La Rosa et al. 1998,2001,2003)
whose biological functions are yet not clear. In addi-
tion, among various growth factors, activin A has
been recently detected by IHC in specific human endo-
crine cell types of the gut and pancreas (La Rosa et al.
1999), and studies in rat pancreas have demonstrated
the expression of the 
 

 
A-subunit and activin A in
some pancreatic islet cells (Yasuda et al. 1993; Ogawa
et al. 1993,1995; Furukawa et al. 1995). Although a
 

 
B-subunit immunoreactivity has been described by
Ogawa et al. (1995) in endocrine cells of rat pancre-
atic islets, to the best of our knowledge the 
 

 
B-subunit
expression in human adult gut and pancreatic endo-
crine cells has never been reported. Follistatin expres-
sion has only been investigated in pancreatic islets
(Ogawa et al. 1993,1995; Wada et al. 1996) of rat
and humans, but data concerning its localization in
human gut endocrine cells are lacking.
 
Endocrine tumors (ETs) of the GEP system are
composed of tumor cells whose morphofunctional
profile reproduces in part that of normal GEP endo-
crine cells from which they derive (Solcia et al. 1999).
Like normal endocrine cells, GEP ETs have been
found to produce several growth factors in addition to
their hormone secretion (Bordi et al. 1998). We have
recently demonstrated that whereas the 
 

 
-subunit of
inhibin is expressed in rare cells of a small number of
GEP ETs, the 
 

 
A-subunit is expressed by several GEP
ETs, including gastrinomas, insulinomas, pancreatic
A-cell tumors, and intestinal EC-cell neoplasms (La
Rosa et al. 1999). However, as far as we know, the
expression of the 
 

 
B-subunit and follistatin in GEP
ETs has not been reported in the English literature.
The present study was designed to localize the three
subunits of inhibin/activin and follistatin in normal
GEP endocrine cells and GEP ETs using IHC and ISH.
 
Materials and Methods
 
Tissues
 
Samples of normal pancreas and gut mucosa and of 65 well-
characterized GEP ETs were collected at surgery. The main
clinicopathological data of patients are summarized in Table
1. Tissues were fixed in buffered formalin (formaldehyde
4% and acetate buffer 0.05 M) for 24 hr and embedded in
paraffin. Sections 5 
 

 
m thick were stained with hematoxy-
lin–eosin (H&E), alcian blue–periodic acid Schiff (AB-PAS),
and Grimelius silver stain for the histopathological examina-
tion.
 
Antibodies
 
The anti-
 

 
-subunit antibody (Serotec; Oxford, UK) was a
mouse monoclonal antibody (MAb) directed against a syn-
thetic protein corresponding to the 1–32 peptide sequence of
the 
 

 
-subunit of 32-kD human inhibin. The mouse MAb di-
rected against the 
 

 
A-subunit (Serotec) recognized a syn-
thetic peptide corresponding to the 82–114 protein sequence
of the 
 

 
A-subunit of 32-kD human inhibin A and activin A.
The anti-
 

 
B-subunit mouse MAb (Serotec) was directed
against a synthetic peptide corresponding to residues 82–
114 of the inhibin 
 

 
B-subunit. The anti-follistatin antibody
was a rabbit polyclonal antiserum recognizing the 27–43
amino acid sequence of rat follistatin (follistatin peptide FP2
of the National Hormone and Pituitary Program; Bethesda,
MD), which is identical to the human amino acid sequence
in this region. Normal endocrine cells and endocrine tumors
were identified and classified using the antibodies and antis-
era listed in Table 2.
 
Riboprobes
 
The sequence of human ovarian 
 

 
-subunit of inhibin (Gen-
Bank accession number M13144) was used to design the
primers to detect the 
 

 
-subunit mRNA in tissue sections: for-
ward primer, 5
 

 
-TGTTCCGGCCATCCCAGCAT-3
 

 
 (298–
317 of sequence); reverse primer, 5
 

 
-ACTGGGTGGTCTG-
GTCCGA-3
 

 
 (632–614 of the sequence). These amplified a
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335-bp segment. The sequence of human inhibin/activin 
 

 
A-
subunit (GenBank accession number BC007858) was used
to design the primers for 
 

 
A-subunit detection: forward
primer, 5
 

 
-GTTGGCAAGTTGCTGGATT-3
 

 
 (256–274 of
the sequence); reverse primer, 5
 

 
-CTCCATAAGTTCAT-
TCATTTC-3
 

 
 (580–560 of the sequence). These amplified a
325-bp segment of the gene. The sequences of human in-
hibin/activin 
 

 
B-subunit gene for exon 1 (GenBank acces-
sion number M31668) and for exon 2 (GenBank accession
number M31669) were used to design the primers for 
 

 
B-
subunit detection: forward primer, 5
 

 
-GAAATCATCAGCT-
TCGCCGAG-3
 

 
 (1190–1210 of the exon 1 sequence); re-
verse primer, 5
 

 
-CGAATGCGGTGCCTGCTGTC-3
 

 
 (500–
481 of the exon 2 sequence). These were used to amplify a
574-bp segment of the gene.
For 
 

 
- and 
 

 
B-subunits, the Stratagene ProSTAR First-
Strand RT-PCR Kit (Stratagene: La Jolla, CA) was used to
make cDNA using 5 
 

 
g of total RNA from normal human
thyroid. Segments were PCR-amplified in a Perkin-Elmer
9600 thermocycler by the following parameters: 94C for 5
min, then 35 cycles of 94C for 1 min, 62C for 1 min, 72C
for 2 min using 5
 

 
l cDNA, 1 pM each primer, 1.25 U Taq
polymerase, and 25 mM MgCl
 
2
 
 in a 50-
 

 
l total reaction us-
ing the RT-PCR kit. For 
 

 
A-subunit, the Stratagene ProSTAR
First-Strand PCR Kit was used to generate cDNA from 5 
 

 
g
of total RNA extracted from a normal human pituitary. The
segment was amplified in a Perkin-Elmer 9600 thermocycler
by the following parameters: 94C for 5 min, then 30 cycles
of 94C for 1 min, 42C for 1 min, 72C for 2 min using 5 
 

 
l
of the cDNA, 50 ng of each primer, 1 
 

 
l dNTP mix (2.5 mM
 
Table 1
 
Main clinicopathological data and activin/inhibin subunit expression in digestive endocrine tumors
 
a
 
Site Type
Sex
M/F
Age (yr) Size (cm)
Metastasis 
or invasion Syndrome
 

 
-subunit
 

 
A-subunit
 

 
B-subunit
FollistatinMean Range Mean Range IHC ISH IHC ISH IHC ISH
Stomach Type 1 1/2 77 65–90 0.8 0.3–2 0/3 0/3 0/3 0/1 1/3 1/1 0/3 1/1 0/3
Type 3 2/1 41 26–56 4.1 2–8.3 3/3 0/3 1/3 1/3 1/3 1/3 0/3 1/3 0/3
Duodenum D-cell 1/3 47 38–52 2.2 1–4 4/4 0/4 0/4 0/3 1/4 3/3 4/4 3/4 0/3
G-cell 1/2 44 36–55 0.9 0.5–1.3 0/3 1/3 1/3 0/2 3/3 2/2 2/2 2/2 0/3
Pancreas G-cell 0/2 55 40–71 1.7 1.5–2 2/2 2/2 1/2 0/2 2/2 2/2 1/2 1/2 0/2
D-cell 0/1 52 5 1/1 1/1 0/1 0/1 0/1 0/1 1/1 1/1 0/1
B-cell 4/6 42 25–51 1.8 1–4 1/10 10/10 0/10 0/10 4/10 6/10 2/10 3/10 0/10
VIPoma 2/1 41 26–57 5 5–5 1/3 3/3 0/3 1/3 2/3 2/3 3/3 3/3 1/3
A-cell 0/4 56 33–66 1.5 1–2 0/4 0/4 0/4 0/4 4/4 4/4 4/4 4/4 0/4
EC-cell 0/1 50 2 0/1 0/1 0/1 0/1 1/1 1/1 1/1 0/1 NE
A/D-cell 0/1 37 6 1/1 0/1 1/1 1/1 1/1 1/1 1/1 1/1 NE
Undefined 1/0 63 3 1/1 0/1 1/1 0/1 1/1 1/1 1/1 1/1 0/1
Ileum EC-cell 6/4 60 39–75 2 1–3 8/9 0/10 0/10 0/9 3/10 5/9 9/10 7/8 0/9
Appendix EC-cell 4/6 33 14–95 0.9 0.2–2 0/10 0/10 0/10 0/5 1/10 2/5 8/9 4/5 0/7
Right colon EC-cell 1/1 48 46–50 5 2–8 2/2 0/3 0/3 0/3 1/3 1/3 2/3 1/2 0/3
Rectum EC-cell 2/0 62 54–70 2 2–2 1/2 0/2 0/2 0/2 0/2 1/2 2/2 2/2 0/2
L-cell 2/2 55 39–66 0.5 0.2–1 0/4 0/4 0/4 0/2 0/4 1/2 3/3 2/2 2/2
Total 25/63 5/65 3/53 26/65 34/53 44/62 37/52 3/56
(39.6%) (7.7%) (5.6%) (40%) (64%) (71%) (71%) (5.3%)
 
a
 
Type 1, ECL-cell tumor associated with chronic atrophic gastritis; type 3, sporadic ECL-cell tumor; yr, year; IHC, immunohistochemistry; ISH, in situ hybridization;
NE, not examined.
 
Table 2
 
Antibodies and antisera employed
 
Antibodies/antisera P/M (clone)
 
a
 
Dilution Source
Insulin M(AE9D6) 1:200 BioGenex Laboratories (San Ramon, CA)
Glucagon P 1:1250 Milab (Malmo, Sweden)
Glucagon/glycentin P 1:2500 Milab
Pancreatic polypeptide P 1:4000 Cambridge Research Biochemicals (Cambridge, UK)
Somatostatin P 1:500 DAKO (Copenhagen, Denmark)
Serotonin M(YC5) 1:50 Biogenesis (Bournemouth, UK)
C-terminus gastrin–CCK–cerulein M(B4) 1:10,000 Farmitalia (Milan, Italy)
Gastric inhibitory peptide (GIP) P 1:10 Milab
Motilin P 1:400 Biogenesis
Secretin P 1:500 Milab
Peptide YY (PYY) P 1:1000 Biogenesis
 

 
-Subunit of inhibin M(R1) 1:100 Serotec (Oxford, UK)
 

 
A-Subunit of inhibin/activin M(E4) 1:100 Serotec
 

 
B-Subunit of inhibin/activin M(C5) 1:100 Serotec
Follistatin P 1:10000 Dr. A. Parlow (National Hormone and Pituitary Program)
 
a
 
P/M, polyclonal/monoclonal.
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each dNTP), 5 
 

 
l cloned Pfu buffer and 1.25 U of cloned
10X Pfu Turbo DNA polymerase (Stratagene) in a 50-
 

 
l re-
action. The PCR products were ligated into the pGEM-T
Easy vector (Promega; Madison, WI). Each ligation was
done using 0.5–2.5
 

 
l of each PCR reaction, 5 
 

 
l 5X Rapid
Ligation Buffer, 3 U T4 DNA Ligase in a 10-
 

 
l reaction vol-
ume for 1 hr at ambient temperature. Three 
 

 
l of each liga-
tion was used to transform Top 10 Ultracompetent 
 
E. coli
 
(Invitrogen; Carlsbad, CA). Plasmids were sequenced by the
Mayo Clinic Molecular Biology Core facility using the pUC/
M13 primer Forward (Promega). The riboprobes were
digoxigenin 11-UTP labeled using the labeling kit purchased
from Boehringer Mannheim (Mannheim, Germany). The
transcription reaction produces either antisense or sense
RNA probe, depending on the orientation of the clonal in-
sert.
 
Immunohistochemistry
 
For IHC staining, 3-
 

 
m-thick sections were mounted on
poly-
 
l
 
-lysine-coated slides, deparaffinized, and hydrated
through graded alcohol to water. After endogenous peroxi-
dase activity inhibition, primary antibody incubation was
done at 4C for 18–20 hr, followed by the avidin–biotin com-
plex (ABC) procedure. Immunoreactions were developed
using 0.03% 3,3
 

 
-diaminobenzidine tetrahydrochloride. Colo-
calization studies were performed using double-label immu-
nostains according to Mason et al. (1983) or Lan et al.
(1995). Sections incubated with antibodies against glucagon
and somatostatin were pretreated for 10 minutes with
0.003% subtilisin (Sigma, St Louis, MO, P4789; protease
type XXVII or Nagarse protease) in 0.05 M Tris-buffered
saline, pH 7.4. Sections stained for the 
 

 
-subunit of inhibin
and 
 

 
A-subunits of inhibin/activin were pretreated with
0.01 M citrate buffer, pH 6, for 10 min in a microwave oven
at 650 W, while those immunostained with the anti-follista-
tin antibodies were pretreated with the same buffer but for
20 min. Sections stained with antibodies against the 
 
B-sub-
unit were pretreated with etylenediaminetetraacetic acid (EDTA)
buffer, pH 8, for 10 min in a microwave oven at 650 W.
Specificity controls consisted of absorption of antibodies
and antisera with 10–20 nM of their related antigens, substi-
tution of the primary antibody with non-immune serum of
the same species at the same dilution, and use of control tis-
sues with or without the pertinent antigen.
In situ hybridization
ISH was performed as previously reported (Lloyd et al.
2001). Briefly, sections were deparaffinized and placed in a
10 mM citrate buffer, pH 6, in a microwave oven at 800 W
power and then treated with proteinase K (Boehringer). Af-
ter incubation in 0.2 N HCl in 0.1 M triethanolamine
with freshly made acetic anhydride and in prehybridization
buffer, hybridization was done at 50C for 16 hr. After
RNase treatment and washing in sodium citrate and sodium
chloride buffer, sections were reacted with anti-digoxigenin
antibody linked to alkaline phosphatase (Roche; Penzberg,
Germany), followed by incubation with nitroblue tetrazo-
lium (NBT) and 5-bromo-4-chloro-3 indolylphosphate (BCIP).
Specificity controls consisted of the omission of the antisense
riboprobe, use of a sense riboprobe, and testing the antisense
in tissues known to express the mRNA.
Results
Normal Tissues
Endocrine cells dispersed along the gut or present in
the pancreatic islets were negative for both -subunit
and follistatin.
Intense cytoplasmic immunoreactivity for the A-
subunit was found in several endocrine cells of the
gastric and duodenal mucosa and in many cells of
pancreatic islets. Conversely, A-subunit immuno-
reactivity was lacking in endocrine cells located in the
other tracts of the gut. Double-label immunostaining
demonstrated that, in antroduodenal mucosa, A-sub-
unit-immunoreactive (IR) cells corresponded to G- (Fig-
ure 1A), EC- (Figure 1B), and GIP-cells (Table 3). Ow-
ing to the rarity of A-subunit-IR cells in the oxyntic
mucosa of the stomach, it was not possible to estab-
lish which type of endocrine cell was expressing the
A-subunit. In the pancreas, A-subunit-IR was
found in cells mainly located at the periphery of the
islets and also in several endocrine cells dispersed
through the exocrine parenchyma. Double-label im-
munostaining demonstrated that A-subunit-IR cells
corresponded mainly to glucagon-producing A-cells
(Figures 1C and 1D).
Immunoreactivity for the B-subunit was mainly
restricted to endocrine cells of the antral and duodenal
mucosa as well as in those of pancreatic islets, but it
was lacking in the other portions of the gut, with the
exception of rare positive cells in the fundic and rectal
mucosa (Table 3). As demonstrated by co-localization
studies, B-subunit-IR, which was intense, cytoplas-
mic, and granular, was localized in somatostatin-pro-
ducing D-cells, both in the antroduodenal mucosa and
in the pancreatic islets (Figures 1E and 1F).
Normal islet cells and normal gut endocrine cells
were mostly negative for -, A-, and B mRNA de-
Figure 1 Double-label immunostaining demonstrates that the A-subunit (red) is co-localized with gastrin (A) and serotonin (B) in some
cells of the antroduodenal mucosa. In normal pancreatic islets, the A-subunit (brown) co-localizes with glucagon (C) but not with pancre-
atic polypeptide (D). The B-chain is expressed by somatostatin-producing cells (E) but not by glucagon-producing cells (F). Pancreatic hor-
mones are stained in red. A pancreatic A-cell tumor shows intense immunoreactivity for the A-subunit (G) and expresses high levels of A-
subunit mRNA (H). High levels of B protein (J) and mRNA (K) were found in a duodenal somatostatin-producing cell tumor. (I,L) Negative
ISH stainings obtained in the same tissues of H and K using the respective sense probes.
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tection. Only in rare endocrine cells was weak positive
ISH staining observed.
Endocrine Tumors
The clinicopathological profile of the 65 ETs investi-
gated is reported in Table 1. Clinically, the majority
(48/65) of tumors were nonfunctioning. The function-
ing neoplasms were represented by three gastrinomas
(one duodenal and two pancreatic), one pancreatic so-
matostatinoma, 10 insulinomas, and three VIPomas,
each of them associated with specific symptoms of the
related syndromes. With the exception of three cases
associated with the MEN 1 syndrome, all tumors were
sporadic. Table 4 summarizes the expression of the
three subunits of inhibin/activin and of follistatin in
relation to the tumor type, independently from the site
of origin.
-Subunit immunoreactivity was found in a few
ETs (5/65, 7.7%), and in these tumors the mean per-
centage of positive cells was 10% (range 3–30%).
-Subunit mRNA was detected by ISH in 3/53 (5.6%)
cases.
Immunoreactivity for the A-subunit was found in
26/65 (40%) ETs and was mainly restricted to G-cell
and A-cell tumors (Figure 1G). However, some tu-
mors of a different type, including four B-cell, six EC-
cell neoplasms, and two VIPomas showed immuno-
reactivity for the A-subunit, although this was less
intense and expressed in fewer tumor cells than in
G-cell and A-cell tumors. By ISH, 34/53 (64%) tu-
mors were positive for mRNA detection and, as for
IHC, A-cell (Figure 1H) and G-cell neoplasms pre-
sented stronger staining in more numerous cells than
the other tumor types.
B-Subunit immunoreactivity was observed in 44/
62 (71%) ETs, including all D-cell, A-cell, L-cell neo-
plasms, and VIPomas, and in the majority (22/25
cases, 88%) of EC-cell tumors. In addition, other
types of ETs, including two insulinomas, one tumor of
undefined cell type, and three G-cell tumors presented
some B-subunit-IR cells; 37/52 (71%) tumors were
positive at ISH investigation and, as shown in Table 4,
there is a good agreement between ISH and IHC re-
sults (Figures 1J and 1K).
Follistatin immunoreactivity was found in only 3/56
(5.3%) ETs, represented by two rectal L-cell tumors
and one pancreatic VIPoma. The mean percentage of
positive cells in L-cell neoplasms was 15%, but in the
VIPoma only rare cells were positive.
Discussion
In the present study we have investigated the expres-
sion of -, A-, and B-subunits of inhibin/activin in
normal endocrine cells and in a series of well-charac-
terized ETs of the digestive system. In addition, we
studied the IHC expression of follistatin in the
same tissues. Considering the molecular homo/het-
erodimeric structure of inhibins and activins, compre-
hensive study of the expression of the three subunits
composing these proteins has enabled us to identify
their exact distribution in both normal and neoplastic
GEP endocrine cells. The co-expression of -subunit
with A- or B-subunit was indicative for the pres-
ence of inhibin A or inhibin B, respectively. On the
other hand, the unique immunoreactivity for A- or
B-subunits was consistent with the presence of ac-
tivin A or activin B. Finally, when A- and B-sub-
units were detected within the same cells, the presence
of activin AB as well as of activin A and activin B was
considered. These data, combined with the functional
characterization of normal and neoplastic endocrine
cells based on the detection of their hormonal produc-
tion, provided a survey of the distribution of various
forms of activins and inhibins in different endocrine
cell types and in various ETs.
Our results indicate that follistatin is not expressed
in normal GEP endocrine cells. In addition, because
we did not identify any -subunit immunoreactivity in
any endocrine cell of the gut and pancreas, we suggest
that inhibins, including inhibin A (-A) and inhibin
Table 3 Immunohistochemical localization of -, A-,
B-subunits of inhibin/activin and follistatin in normal 
endocrine cells of gut and pancreasa
Site -Subunit A-Subunit B-Subunit Follistatin
Fundus  Rare Rare 
Antrum  G, EC D 
Duodenum  G, EC, GIP D 
Pancreas  A D 
Jejunum    
Ileum    
Appendix    
Colon    
Rectum   Rare 
aG, gastrin-producing G-cells; EC, serotonin-producing EC-cells; GIP, gastric in-
hibitory peptide-producing GIP-cells; A, glucagon-producing A-cells; D, soma-
tostatin-producing D-cells.
Table 4 Activin and inhibin subunit expression in relation to 
tumor cell type
Cell type
-Subunit A-Subunit B-Subunit
FollistatinIHC ISH IHC ISH IHC ISH
ECL-cell 1/6 1/4 2/6 2/4 0/6 2/4 0/6
D-cell 0/5 0/4 1/5 3/4 5/5 4/4 0/4
G-cell 2/5 0/4 5/5 4/4 3/4 3/4 0/5
B-cell 0/10 0/10 4/10 6/10 2/10 3/10 0/10
A-cell 1/5 1/5 5/5 5/5 5/5 5/5 0/5
Vipoma 0/3 1/3 2/3 2/3 3/3 3/3 1/3
EC-cell 0/26 0/20 6/26 10/20 22/25 14/18 0/21
L-cell 0/4 0/2 0/4 1/2 3/3 2/2 2/2
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B (-B), are not expressed in these cells. On the other
hand, our results have shown that activin A (A-A)
and activin B (B-B) are differently expressed in GEP
endocrine cells. In particular, activin A is expressed by
G-, EC-, and GIP-cells of the antral and duodenal mu-
cosa and in A-cells of the pancreatic islets, while ac-
tivin B expression is restricted to duodenal and pan-
creatic somatostatin-producing D-cells.
Our findings concerning the A-subunit distribu-
tion are in agreement with several recent IHC studies
in which tissues of adult humans and of adult or fetal
rats were investigated. We have identified activin A in
gut G-, EC-, and GIP-cells, confirming our previous
results (La Rosa et al. 1999). The expression of activin
A in pancreatic A-cells fits well with findings reported
in previous studies (Ogawa et al. 1993,1995; Yasuda
et al. 1993; Furukawa et al. 1995; La Rosa et al.
1999), although Wada et al. (1996), in their IHC in-
vestigation, observed activin A immunoreactivity only
in insulin-producing B-cells of the pancreas. These dif-
ferent results may be explained by considering the dif-
ferent antibodies employed. In addition, one must
consider that activin A and glucagon have been dem-
onstrated to be pooled within the same granules (Ver-
spohl et al. 1993), suggesting that they may have a
synergistic action in the control of glucose metabo-
lism.
The B-subunit of inhibin/activin has been previ-
ously localized in A- and B-cells of rat pancreatic islets
(Ogawa et al. 1995), but data concerning its distribu-
tion in human gut and pancreatic endocrine cells are
lacking. Our study has demonstrated, for the first
time, that duodenal and pancreatic somatostatin-pro-
ducing D-cells are strongly immunoreactive for the
B-subunit, suggesting that this cell type expresses ac-
tivin B. This finding, which is different from that ob-
served by Ogawa et al. (1995) in rat pancreatic tis-
sues, may be due to the difference in the species
investigated or in the antibodies employed.
Our findings regarding the localization of follistatin
in pancreatic endocrine cells are unlike those reported
in previous studies (Ogawa et al. 1993,1995; Wada et
al. 1996). In fact, we did not observe any follistatin
immunoreactivity in pancreatic endocrine cells and in
gut endocrine cells. On the contrary, follistatin immu-
noreactivity has been reported in both human (Wada
et al. 1996) and rat (Ogawa et al. 1993) pancreatic
B-cells. Ogawa et al. (1995) demonstrated that rat pan-
creatic B-cells were positive for follistatin when tested
with antibodies detecting the short form of the mole-
cule, whereas they were negative when tested with the
antibodies detecting the long form. Using a rabbit
polyclonal antibody raised against a recombinant fol-
listatin, Wada et al. (1996) observed follistatin immu-
noreactivity in human pancreatic B-cells. In our study,
we employed an antiserum against the 27–43 amino
acid sequence of follistatin, which is present in both
the short and long form of the molecule. The specific-
ity of our antiserum was demonstrated by the staining
in normal tissue, including pituitary and ovary, and
negative staining of the same tissues after incubation
of the antiserum with both specific sequence peptide
and recombinant follistatin, which abolished the posi-
tivity. The discrepancies between our results and those
above described (Ogawa et al. 1993,1995; Wada et al.
1996) may be mainly due to the different antibodies
employed. The absence of immunoreactivity for fol-
listatin that we observed in gut endocrine cells cannot
be compared with other findings because of the lack
of previous studies on this subject.
ISH investigation did not reveal significant mRNA
expression in normal GEP endocrine cells, in contrast
to IHC, which demonstrated, as discussed above, a
specific distribution of the different subunits among
various normal endocrine cells. The lack of mRNA in
normal tissues was not due to a general mRNA degra-
dation, because other probes that we used in our lab,
such as proinsulin or myosin XVA probes (data not
shown), gave strong staining in the same tissues (La
Rosa et al. 2002). In addition, several peritumoral
normal tissues that we investigated were negative
although the adjacent tumor cells showed different
degrees of ISH staining. Using Northern blotting anal-
ysis, Kleeff et al. (1998) have recently found overex-
pression of mRNA encoding various subunits of in-
hibin and activin in pancreatic cancers in contrast
with adjacent normal pancreatic tissues. In this study,
very low levels of A-, B-, and -subunit mRNA
were found in normal pancreas, in contrast with the
high expression in pancreatic cancers. Studies on por-
cine tissues have also demonstrated that activin A and
B mRNAs are not expressed at significant levels in gut
mucosa (Schneider et al. 2000).The very low level of
mRNA found in normal tissues reported above is well
in agreement with our data. Conversely, the IHC ex-
pression of various subunits is well demonstrated by
our and other investigations (Ogawa et al. 1993,1995;
Yasuda et al. 1993; Furukawa et al. 1995; La Rosa et
al. 1999). Discrepancies in the localization patterns of
mRNA and corresponding proteins have also been
noted with members of the TGF superfamily, includ-
ing inhibins and activins in embryonic (Akhurst et al.
1990; Jakowlew et al. 1994) and ovarian (Benhamed
et al. 1993; Roberts et al. 1993,1994) tissues. Such
discrepancies may be explained by several mecha-
nisms: (a) the level of mRNAs may be below the detec-
tion limit of the assay procedures; (b) synthesized pro-
teins have been stored in cells for a long time and no
newly mRNA synthesis is required; or (c) in tumor
cells mRNA may be overexpressed because of the high
metabolic activity of neoplastic cells.
The biological meaning of the different distribution
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of activin proteins, either activin A or activin B, and
the lack of inhibins and follistatin expression, which
we observed in GEP endocrine cells, is yet not clear.
The localization of activin A in glucagon-producing
A-cells and gastric inhibitory peptide (GIP)-producing
cells, which are well-known regulators of glucose me-
tabolism (Duprè et al. 1973; Unger and Orci 1976; El-
hai et al. 1979; Creutzfeldt and Ebert 1985) suggests
that this factor may participate with glucagon and GIP
in the same physiological mechanism. In this context,
it is worth noting that activin A has been demon-
strated to induce insulin secretion from both rat (Tot-
suka et al. 1988) and human pancreatic islets (Florio
et al. 2000). In addition, transgenic mice with muta-
tion of the activin receptor have a lower survival rate
with smaller islet area and impaired glucose tolerance
(Yamaoka et al. 1998). These data suggest a role for
activin in modulating islet function as a local auto-
crine and/or paracrine factor.
The biological role of activin B expression is less
clear. Because we observed its expression in soma-
tostatin-producing D-cells, we can hypothesize that
activin B may be involved, together with somatostatin,
in the regulation of some endocrine cell functions, al-
though its role remains to be elucidated.
On the basis of our negative findings, follistatin
and inhibins do not appear to be involved in the regu-
lation of endocrine cells of the gut and pancreas. Inter-
estingly, both these peptides have inhibitory effects,
through different molecular mechanisms, on activin
functions. Inhibins antagonize activin actions, having
an opposite biological function on the same target
cells, while follistatin inhibits activin actions by di-
rectly binding to it. It can be hypothesized that, in
GEP endocrine cells, activin actions may be modu-
lated by other systems, possibly through a specific re-
ceptor or heparan sulfate proteoglycans, which are
also involved in the modulation of activin activities
(Halvorson and DeCherney 1996).
In addition to normal tissues, we have investigated
a large series (65 cases) of well-characterized ETs. The
distribution of various subunits of inhibin/activin in
GEP ETs partly reflects that observed in normal tis-
sues. Activin A was detected in all G-cell and A-cell
neoplasms and activin B in all D-cell tumors, reflecting
the distribution of these factors in the relative normal
endocrine cells. Activin B expression (B-subunit im-
munoreactivity) was unexpectedly detected in pancre-
atic A-cell, rectal L-cell, and in the majority (22/25,
88%) of the intestinal EC-cell tumors. Considering
that the relative normal cells did not show any B-
chain expression, this discrepancy between normal
and neoplastic cells may represent a “de novo” ex-
pression of activin B in tumor cells or, more likely, an
overexpression of this peptide in tumors from low
level, poorly detectable, present in normal cells.
We have not found any relationship between ac-
tivin expression and malignancy, suggesting that it
does not have a role in ET aggressiveness. This is in
contrast to the data recently reported by Salmenkivi et
al. (2001), who observed an inverse relationship be-
tween activin B expression and malignancy in adrenal
pheochromocytomas.
In conclusion, in this study we have demonstrated
that activins are specifically expressed by various en-
docrine cells of the GEP system, suggesting that they
may participate in the modulation of physiological
functions of these cells. In addition, ETs tend to ex-
press the same type of activin identified in their puta-
tive cells of origin. These findings suggest that activins
may have a role in the biology and pathogenesis of
ETs of the GEP system.
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